CASI Pharmaceuticals (CASIF) Operating Leases (2021 - 2025)

CASI Pharmaceuticals has reported Operating Leases for 5 years, with the latest figure at $1.4 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases fell 43.16% year-over-year to $1.4 million; the trailing twelve-month figure through Dec 2025 stood at $1.4 million (down 43.16% YoY), and the FY2025 full-year result was $1.4 million, down 43.16% from the prior year.
• Operating Leases for Q4 2025 stood at $1.4 million, down from $2.5 million in the prior quarter.
• The five-year high for Operating Leases was $2.5 million in Q4 2024, with the low at $476000.0 in Q4 2022.
• Historically, Operating Leases has averaged $1.4 million across 5 years, with a median of $1.4 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Leases plunged 56.92% — and 2023, when it jumped 239.5%.
• CASI Pharmaceuticals' Operating Leases stood at $1.1 million in 2021, then sank by 56.92% to $476000.0 in 2022, then jumped by 239.5% to $1.6 million in 2023, then soared by 56.87% to $2.5 million in 2024, then tumbled by 43.16% to $1.4 million in 2025.
• The last three Operating Leases figures came in at $1.4 million (Q4 2025), $2.5 million (Q4 2024), and $1.6 million (Q4 2023), per Business Quant data.